HPLC analysis of recombinant Botulinum neurotoxins: expanding the analytical toolbox

Malgorzata Field^{*}, James Cummins, Imran Mir, Andrew Splevins, Andy Hooker

Ipsen Bioinnovation Limited, 102 Park Drive, Milton Park, Abingdon, OX14 4RY, UK

Introduction and Objectives

- High Performance Liquid Chromatography (HPLC) is a powerful tool widely used in the pharmaceutical industry to assess process and product-related impurities within different molecules. ⁽¹⁾
- Methods used to monitor different purity attributes of molecules such as size, aggregation, shape, truncation, hydrophobicity etc.
- Chromatographic separation of toxins carries multiple technical challenges to equipment set-up and consideration of assay design.
- Having found solutions to overcome the safety challenges, here we present Reverse Phase (RP) HPLC and Size Exclusion (SE) HPLC methods developed for various serotypes of recombinant Botulinum neurotoxins (BoNTs) and novel re-targeted BoNTs (Targeted Secretion Inhibitors- [TSI]).



Methods

Safety considerations

Table 1. Safety considerations prior to HPLC analysis of BOINTS	Table 1.	Safety	considerations	prior to	HPLC ana	lysis of BoNT
--	----------	--------	----------------	----------	----------	---------------

Challenge	Solution	
User safety during HPLC analysis of BoNTs	The whole HPLC system enclosed in the safety cabinet	
Best practise - HPLC mobile phase stored in glass containers → risk of injury from sharps	Solvent resistant plastic sourced and proved to be fit for purpose	
Solvent containing BoNT waste decontamination	Segregated waste stream established for off-site destruction	
Decontamination of the HPLC system	Safe and effective decontamination procedure in place	

Presented at TOXINS, 18-21 January 2017, Madrid, Spain.



Size exclusion HPLC

• Aggregation assay.

Separation based on size of molecules. Smaller particles can enter the beads of the resin and subsequently elute later than larger particles which are excluded from more of the column volume.

- The following parameters were optimised:
 - -column selection (industry standards)
 - -mobile phase components and concentrations
 - -sample preparation

BoNTs are prone to secondary interactions with the surface of stationary phase, mainly due to electrostatic and hydrophobic interactions which results in peak shape changes, such as tailing. A common approach to mitigate this involves an increase of the ionic strength of the mobile phase and addition of modifiers, such as organic solvents or arginine. ⁽²⁾

• Assay's performance in terms of precision and linearity was assessed.

Reverse phase HPLC

Figure 4. Separation of BoNT by RP HPLC under reducing and nonreducing conditions

> Blue- separation under non-reducing condition **Red- separation under reducing condition** Intact BoNT

Table 2. Results for the RP HPLC assay

d attribute	Method parameter varied	Result	
er (retention erial on the olumn)	Column selection, temperature, washing procedure	Carryover decreased from 60% to less than 1%	
k shape	Column selection, temperature	Sharper peak and better symmetry at higher temperature	
resolution	Acetonitrile gradient	Multiple step gradient- good separation without a significant increase in run time	
uction of hide bond	Reducing agents screen	Full activation achieved without protein precipitation	

Size exclusion HPLC

Black-BoNT



Conclusions

- process review.

References 'Methods in molecular biology, vol251'

Scan here to view a PDF of this poster

Copies of this poster obtained through Quick Response Code are for personal use only



Column selection based on manufacturer's claimed molecular weight range was confirmed using protein standards (Bio-Rad).

In the initial testing of sodium chloride concentration progressively increasing peak height with less tailing was observed with the increasing salt. Further increase of ionic strength of the mobile phase

did not bring any improvement of tailing.

• Addition of arginine was found to sufficiently mitigate unspecific interaction with the column resulting in good peak shape.

• Prior to introducing any of the new chromatographic separation methods, it was necessary to perform rigorous safety checks and

• Solutions were found to overcome technical issues allowing chromatographic analysis of BoNTs.

• A suite of analytical chromatography methods has been developed allowing assessment of purity and impurity profiles of rBoNTs and TSIs. • Certain elements of assay development are transferable across

multiple serotypes but individual optimisation is required. • Precision and linearity of developed assays were assessed and assays proved to be suitable for qualification.

1 'HPLC of peptides and proteins methods and protocols' Marie-Isabel Aguilar from

2 'A review size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates' P. Hong et al, 2012